Browsing Centre for Genomics and Child Health by Author "Hakim, J"
Now showing items 1-3 of 3
-
Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.
Post, FA; Szubert, AJ; Prendergast, AJ; Johnston, V; Lyall, H; Fitzgerald, F; Musiime, V; Musoro, G; Chepkorir, P; Agutu, C (Oxford University Press (OUP), 2018-03-04)Background: In sub-Saharan Africa, 20%-25% of people starting antiretroviral therapy (ART) have severe immunosuppression; approximately 10% die within 3 months. In the Reduction of EArly mortaLITY (REALITY) randomized ... -
Enhanced infection prophylaxis reduces mortality in severely immunosuppressed HIV-infected adults and older children initiating antiretroviral therapy in Kenya, Malawi, Uganda and Zimbabwe: the REALITY trial
Hakim, J; Musiime, V; Szubert, AJ; Siika, A; Mallewa, J; Agutu, C; Pett, SL; Bwakura-Dangarembizi, M; Lugemwa, A; Kaunda, S (Wiley on behalf of International AIDS Society, 2016-07-22)Meeting abstract FRAB0101LB from 21st International AIDS Conference 18–22 July 2016, Durban, South Africa. Introduction: Mortality from infections is high in the first 6 months of antiretroviral therapy (ART) among ... -
Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa
Hakim, J; Musiime, V; Szubert, AJ; Mallewa, J; Siika, A; Agutu, C; Walker, S; Pett, SL; Bwakura-Dangarembizi, M; Lugemwa, A (2017-07-20)